Soligenix data-enriched by China mucositis deal with SciClone
This article was originally published in Scrip
Executive Summary
As part of a strategy to focus solely on developing its Chinese commercial business, the US firm SciClone Pharmaceuticals has signed its third licensing deal in the past three months, this time acquiring rights in China to Soligenix' innate defense regulator for oral mucositis SGX942.